#France #Pierre Fabre #Castres #PFL-721 #PFL-241

Pierre Fabre Laboratories Strengthens R&D Portfolio with Strategic Acquisition

Pierre Fabre Laboratories has proudly announced a significant expansion of its research and development (R&D) capabilities through the acquisition of worldwide rights for PFL-721 and PFL-241 from Antares Therapeutics, Inc. This strategic move is part of Pierre Fabre's commitment to address urgent medical needs in the treatment of non-small cell lung cancer (NSCLC).

New Developments in Lung Cancer Treatment

PFL-721 is an innovative drug designed as a mutant-specific EGFR exon-20 and HER2 exon-20 inhibitor, currently transitioning to dose optimization within its first human trials for NSCLC. Meanwhile, PFL-241 acts as a mutant-specific, brain-penetrant, fourth-generation EGFR inhibitor, actively undergoing dose escalation in clinical trials to combat C797S resistance mutations observed in NSCLC patients.

NSCLC, the predominant subtype of lung cancer, is significantly influenced by various EGFR mutations that are frequently the driving force behind the disease, with such mutations occurring in approximately 14-38% of tumors, depending on geographic variations. This illustrates a pressing need for advanced treatment options that target these specific mutations effectively.

Enhancing Pierre Fabre's R&D Initiatives

Francesco Hofmann, the Head of Research and Development for Medical Care at Pierre Fabre Laboratories, expressed the organization’s enthusiasm about this acquisition, stating, “With this agreement with Antares, Pierre Fabre Laboratories now owns the global rights for all the assets within our R&D portfolio including exarafenib, PFL-002, PFL-721, and PFL-241. Our R&D team is fully engaged and committed to advancing these clinical programs, aiming to deliver novel precision medicines to patients with significant unmet needs.”

This acquisition aligns with Pierre Fabre’s overarching strategy to enhance its R&D capabilities, ensuring that the company can continue to push the boundaries of science and improve the lives of patients worldwide.

About Pierre Fabre Laboratories

As the second-largest dermo-cosmetics company globally and a leading player in Europe’s pharmaceutical sector, Pierre Fabre Laboratories showcases a diverse portfolio that includes several renowned international brands such as Eau Thermale Avène, Klorane, A-Derma, and Ducray. Additionally, their Medical Care segment focuses on critical therapeutic fields like oncology, dermatology, rare diseases, and family health care.

The ongoing developments for PFL-721 and PFL-241 reflect the company’s commitment to innovation in drug therapy and its mission to address some of the most challenging health issues faced by patients today. As Pierre Fabre Laboratories embarks on this promising journey, the global healthcare community will be watching closely to see how these therapies can change the landscape of non-small cell lung cancer treatment.

For further information on this groundbreaking acquisition and the ongoing research at Pierre Fabre Laboratories, visit their website or follow up on recent press releases.